Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
Zura Bio's Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in hidradenitis suppurativa missed its primary endpoint, with AN-count reductions of 56.0% (300 mg) and 58.1% (150 mg) versus 52.5% on placebo; HiSCR50 and HiSCR75 secondary endpoints were also not met. Zura is discontinuing development of tibulizumab in HS, but will continue the ongoing TibuSURE trial in systemic sclerosis (data H1 2027) and the planned NEXUS-PMR study in polymyalgia rheumatica (data Q4 2028).
Key figures
- Drug Name
- tibulizumab (ZB-106)
- Phase Of Trial
- Phase 2
- Cash runway
- sufficient through at least end of 2028
- Hiscr50 150mg
- 52.7%
- Hiscr50 300mg
- 48.0%
- Hiscr75 150mg
- 34.0%
- Hiscr75 300mg
- 35.3%
- Hiscr50 placebo
- 45.5%
- Hiscr75 placebo
- 28.1%
- Cash and equivalents
- 187700000
- Enrolled participants
- 247
- An count reduction 150mg
- 58.1%
- An count reduction 300mg
- 56.0%
- An count reduction placebo
- 52.5%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.